Leveraging location, low costs, and strong legacy companies with a skilled labour pool, the pharmaceutical industry is a quiet success story in Central and Eastern Europe (CEE). The sector is a major contributor to exports and R&D spending in several countries, and has become a magnet for M&A deals in recent years.
Iran’s limited use of violence in the Gulf has caused US President Donald Trump to adopt a more cautious posture towards Tehran. However, conflict is likely to erupt again as long as the economic sanctions remain in place. Iran has begun violating the Joint Comprehensive Plan of Action (JCPOA), with the aim of pressuring the international community to break the blockade and may even be willing to risk a “limited” conflict. In the US, while the prospect of elections in 2020 is likely prevent the Trump administration from hardening its stance in the short run, if it wins a second term and Iran continues its provocations, the anti-Iran hawks in the Cabinet will have maximum flexibility to make the case for military action.